Compounds of reverse turn mimetics and the use thereof (2)

Details Compounds of reverse turn mimetics and the use thereof (2) Compounds of reverse turn mimetics and the use thereof (2)

2008-10-15

2011-12-06

Balasubramanian, Venkataraman (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Four or more ring nitrogens in the bicyclo ring system

C514S243000

Reexamination Certificate

active

08071764

ABSTRACT:
Conformationally constrained compounds that are novel and mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins and having bicyclic frame-work are disclosed, as well as their prodrugs. Such reverse-turn mimetic structures and prodrugs have utility over a wide range of fields, including use as diagnostic and therapeutic agents. The invention also relates to the use of such compounds for the preparation of a medicament for treating or preventing cancer including an acute myeloid leukemia.

REFERENCES:
patent: 5440013 (1995-08-01), Kahn
patent: 5929237 (1999-07-01), Kahn
patent: 6013458 (2000-01-01), Kahn et al.
patent: 7232822 (2007-06-01), Moon et al.
patent: 7566711 (2009-07-01), Moon et al.
patent: 7576084 (2009-08-01), Moon et al.
patent: 7671054 (2010-03-01), Moon et al.
patent: WO-94/03494 (1994-02-01), None
patent: WO-01/00210 (2001-01-01), None
patent: WO-01/16135 (2001-03-01), None
patent: WO 03/031448 (2003-04-01), None
patent: WO 2005/116032 (2005-12-01), None
Tumelty et al, “Immobilised, Activated Peptides as Reagents for Cyclic and Derivatised Peptide Libraries,”J. Chem. Soc., Chem. Commun., pp. 1067-1070, 1994.
Eichler et al., “Cyclic Peptide Template Combinatorial Libraries: Synthesis and Identification of Chymotrypsin Inhibitors,”Peptide Research, 7:300-306, 1994.
Obrecht et al., “Novel Peptide Mimetic Building Blocks and Strategies for Efficient Lead Finding,”Advances in Medicinal Chemistry, Vo. 4, pp. 1-68, 1999.
Pelengaris et al., “The many faces of c-MYC,”Archives of Biochemistry and Biophysics, vol. 416, pp. 129-136, 2003.
Hoffman et al., “The proto-oncogene c-mycin hematopoietic development and leukemogenesis,”Oncogene, vol. 21, pp. 3414-3421, 2002.
Luo et al., “c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations,”Blood, vol. 106, No. 7, pp. 2452-2461, Oct. 1, 2005.
Nakamura et al., “Trimethadione Metabolism, A Useful Indicator for Assessing Hepatic Drug-Oxidizing Capacity,”Biochemical Pharmacology, vol. 47, No. 2, pp. 247-251, 1994.
Rendic et al., “Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and Inhibitors,”Drug Metabolism Reviews, vol. 29 (1&2), 413-580 (1997).
Dresser et al., “Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition,”Clin Pharmacokinet, vol. 38 pp. 41-57, Jan. 2000.
Cheng et al., “Effects of renal function on recainam pharmacokinetics and pharmacodynamics,”Clinical Pharmacology&Therapeutics, vol. 567, No. 5, pp. 492-498, May 1995.
Fleisher et al., “Improved oral drug delivery: solubility limitations overcome by the use of prodrugs,”Advanced Drug Delivery Reviews, pp. 115-130, 1996.
Davis et al., “ZD6126: A Novel Vascular-targeting Agent That Causes Selective Destruction of Tumor Vasculature,”Cancer Research, vol. 62, pp. 7247-7253, Dec. 15, 2002.
Golik et al., “Synthesis and Antitumor Evaluation of Paclitaxel Phosphonooxymethyl Ethers: A Novel Class of Water Soluble Paclitaxel Pro-Drugs,”Bioorganic&Medicinal Chemistry Letters, vol. 6, No. 15, pp. 1837-1842, 1996.

Affiliated with

Also associated with

Rating

Compounds of reverse turn mimetics and the use thereof (2) does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds of reverse turn mimetics and the use thereof (2), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds of reverse turn mimetics and the use thereof (2) will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4303398